Ian D. Miller - 05 Aug 2022 Form 4 Insider Report for SANUWAVE Health, Inc. (SNWV)

Role
Director
Signature
/s/ Griffin D. Foster as Attorney-in-Fact for Ian D. Miller
Issuer symbol
SNWV
Transactions as of
05 Aug 2022
Net transactions value
+$11,025,107,495
Form type
4
Filing time
24 Mar 2025, 16:06:19 UTC
Previous filing
24 Mar 2025
Next filing
07 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNWV Common Stock Award $120,750 +8,050 +44% $15.00 26,509 05 Aug 2023 Direct F1
transaction SNWV Common Stock Award $57,495 +3,833 +14% $15.00 30,342 09 May 2024 Direct F2
transaction SNWV Common Stock Award +6,300 +21% 36,642 18 Oct 2024 Direct F3
transaction SNWV Common Stock Award +5,950 +16% 42,592 18 Oct 2024 Direct F3
transaction SNWV Common Stock Award +3,000 +7% 45,592 18 Oct 2024 Direct F3
transaction SNWV Common Stock Award +2,834 +6.2% 48,426 18 Oct 2024 Direct F3
holding SNWV Common Stock 890 05 Aug 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNWV Future Advance Convertible Promissory Note Award $11,025,000,000 +105,000 $105000.00 $105,000 05 Aug 2022 Common Stock 7,000 $15.00 Direct F4
transaction SNWV Future Advance Convertible Promissory Note Conversion of derivative security $120,750 0 05 Aug 2023 Common Stock 8,050 $15.00 Direct F1
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +7,000 7,000 05 Aug 2022 Common Stock 7,000 $15.00 Direct F4
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -7,000 -100% 0 18 Oct 2024 Common Stock 7,000 $15.00 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +7,000 7,000 05 Aug 2022 Common Stock 7,000 $25.13 Direct F4
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -7,000 -100% 0 18 Oct 2024 Common Stock 7,000 $25.13 Direct F3
transaction SNWV Future Advance Convertible Promissory Note Award $50,000 $50,000 09 May 2023 Common Stock 3,333 $15.00 Direct F5
transaction SNWV Future Advance Convertible Promissory Note Conversion of derivative security $0 -57,500 -100% $0.000000 0 09 May 2024 Common Stock 3,833 $15.00 Direct F2
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +3,333 3,333 09 May 2023 Common Stock 3,333 $15.00 Direct F5
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -3,333 -100% 0 18 Oct 2024 Common Stock 3,333 $15.00 Direct F3
transaction SNWV Common Stock Purchase Warrant (right to buy) Award +3,333 3,333 09 May 2023 Common Stock 3,333 $25.13 Direct F5
transaction SNWV Common Stock Purchase Warrant (right to buy) Disposed to Issuer -3,333 -100% 0 18 Oct 2024 Common Stock 3,333 $25.13 Direct F3
transaction SNWV Stock Option (right to buy) Award $0 +41,333 $0.000000 41,333 22 Oct 2024 Common Stock 41,333 $14.20 Direct F6
transaction SNWV Stock Option (right to buy) Award $0 +1,754 +4.2% $0.000000 43,087 31 Dec 2024 Common Stock 1,754 $22.76 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the terms of the Future Advance Convertible Promissory Note issued by SANUWAVE Health, Inc. (the "Company") on August 5, 2022, all principal and accrued interest due as of the maturity date, August 5, 2023, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
F2 Pursuant to the terms of the Future Advance Convertible Promissory Note issued by the Company on May 9, 2023, all principal and accrued interest due as of the maturity date, May 9, 2024, was automatically converted into shares of common stock at a conversion price of $15.00 per share.
F3 On October 18, 2024, effective upon the Company's 1-for-375 reverse stock split, the reporting person's warrants were exchanged for an aggregate of 18,084 shares of common stock pursuant to a letter agreement between the reporting person and the Company.
F4 On August 5, 2022, in exchange for $105,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $105,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 7,000 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 7,000 shares of common stock at an exercise price of approximately $25.13 per share).
F5 On May 9, 2023, in exchange for $50,000 in cash, the reporting person acquired from the Company a Future Advance Convertible Promissory Note with a principal amount of $50,000 and a conversion price of $15.00 per share of common stock and two warrants (one exercisable for 3,333 shares of common stock at an exercise price of $15.00 per share and the other exercisable for 3,333 shares of common stock at an exercise price of approximately $25.13 per share).
F6 Options will vest over a period of three years in 12 equal installments on each quarterly anniversary of the grant date.
F7 Options were fully vested at the grant date.

Remarks:

All share amounts, exercise prices and conversion prices herein have been retroactively adjusted to reflect the 1-for-375 reverse stock split of the Company's common stock which occurred on October 18, 2024.